Cargando…
Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier España, S.L.U.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296499/ https://www.ncbi.nlm.nih.gov/pubmed/35933189 http://dx.doi.org/10.1016/j.medcli.2022.05.016 |
| _version_ | 1784750287927377920 |
|---|---|
| author | Kow, Chia Siang Ramachandram, Dinesh Sangarran Hasan, Syed Shahzad |
| author_facet | Kow, Chia Siang Ramachandram, Dinesh Sangarran Hasan, Syed Shahzad |
| author_sort | Kow, Chia Siang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9296499 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier España, S.L.U. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92964992022-07-20 Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic Kow, Chia Siang Ramachandram, Dinesh Sangarran Hasan, Syed Shahzad Med Clin (Barc) Letter to the Editor Elsevier España, S.L.U. 2022-11-11 2022-07-20 /pmc/articles/PMC9296499/ /pubmed/35933189 http://dx.doi.org/10.1016/j.medcli.2022.05.016 Text en © 2022 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Kow, Chia Siang Ramachandram, Dinesh Sangarran Hasan, Syed Shahzad Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic |
| title | Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic |
| title_full | Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic |
| title_fullStr | Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic |
| title_full_unstemmed | Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic |
| title_short | Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic |
| title_sort | direct oral anticoagulants (doac) for patients with atrial fibrillation during the covid-19 pandemic |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296499/ https://www.ncbi.nlm.nih.gov/pubmed/35933189 http://dx.doi.org/10.1016/j.medcli.2022.05.016 |
| work_keys_str_mv | AT kowchiasiang directoralanticoagulantsdoacforpatientswithatrialfibrillationduringthecovid19pandemic AT ramachandramdineshsangarran directoralanticoagulantsdoacforpatientswithatrialfibrillationduringthecovid19pandemic AT hasansyedshahzad directoralanticoagulantsdoacforpatientswithatrialfibrillationduringthecovid19pandemic |